Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.

Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, Hickson ID.

Cancer Res. 1991 Dec 15;51(24):6592-5.

3.

Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.

Lelièvre S, Benchokroun Y, Larsen AK.

Mol Pharmacol. 1995 May;47(5):898-906.

PMID:
7746278
4.

Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.

Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radcliffe A, Beran M, Blick M.

J Biol Chem. 1989 Oct 5;264(28):16411-20.

5.

HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.

Zwelling LA, Slovak ML, Doroshow JH, Hinds M, Chan D, Parker E, Mayes J, Sie KL, Meltzer PS, Trent JM.

J Natl Cancer Inst. 1990 Oct 3;82(19):1553-61.

PMID:
1976136
7.

Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.

Nakamura K, Sugumi H, Yamaguchi A, Uenaka T, Kotake Y, Okada T, Kamata J, Niijima J, Nagasu T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K.

Mol Cancer Ther. 2002 Jan;1(3):169-75.

8.

Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.

Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T, Saijo N.

J Natl Cancer Inst. 1992 Jan 15;84(2):113-8.

PMID:
1310509
9.

Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.

Takano H, Kohno K, Ono M, Uchida Y, Kuwano M.

Cancer Res. 1991 Aug 1;51(15):3951-7.

10.
11.

Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.

Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.

Cancer Res. 1998 Apr 1;58(7):1460-8.

12.

Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines.

Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchars KL, Freedman MH, Goldenberg GJ.

Cancer Res. 1995 Jan 1;55(1):78-82.

14.

Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.

Spiridonidis CA, Chatterjee S, Petzold SJ, Berger NA.

Cancer Res. 1989 Feb 1;49(3):644-50.

15.

Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.

Per SR, Mattern MR, Mirabelli CK, Drake FH, Johnson RK, Crooke ST.

Mol Pharmacol. 1987 Jul;32(1):17-25.

PMID:
3037302
16.

Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.

Yamazaki K, Isobe H, Hanada T, Betsuyaku T, Hasegawa A, Hizawa N, Ogura S, Kawakami Y.

Cancer Chemother Pharmacol. 1997;39(3):192-8.

PMID:
8996519
18.
19.
20.

The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.

Lanza A, Tornaletti S, Stefanini M, Evans HH, Ricanati M, Astaldi Ricotti GC, Pedrini AM.

Carcinogenesis. 1993 Sep;14(9):1759-63.

PMID:
8403196

Supplemental Content

Support Center